Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLNCE0)

• Drug Name: Cetuximab Drug Info
• Synonyms: Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Approved	[1]
Laryngeal squamous cell carcinoma		Approved	[2]
Lung cancer	2C25.0	Approved	[3]
Plasma cell myeloma	2A83.1	Approved	[4]
Salivary gland squamous cell carcinoma		Approved	[5]
Colon cancer	2B90.Z	Investigative	[6]
Gastric cancer	2B72	Investigative	[7]
Pharyngeal squamous cell carcinoma		Investigative	[8]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID: TTD Drug ID: DMLNCE0

Molecule-Related Drug Atlas

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[10]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[11]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[12]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[13]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[14]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[15]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[16]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[17]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[15]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Not Available	[9]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6882).
• [2] Cetuximab enhances oridonin-induced apoptosis through mitochondrial pathway and endoplasmic reticulum stress in laryngeal squamous cell carcinoma cells. Toxicol In Vitro. 2020 Sep;67:104885.
• [3] Cetuximab for treating non-small cell lung cancer. Expert Opin Biol Ther. 2018 Apr;18(4):483-493.
• [4] SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity. Front Immunol. 2022 Oct 10;13:989895.
• [5] Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification. Med. 2023 May 12;4(5):290-310.e12.
• [6] Colon cancer. Crit Rev Oncol Hematol. 2010 May;74(2):106-33.
• [7] Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015 Nov;28(11):1481-91.
• [8] Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020 Nov 26;6(1):92.
• [9] Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14.
• [10] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [11] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [12] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [13] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [14] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [16] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [17] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [18] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).